The study found that participants on donepezil experienced a slower progression to Alzheimer's disease compared to those on placebo, with an average delay of 661 days. However, the effects were only observed during the first half of the study and further analyses are needed to confirm these findings.
A recent study demonstrated that a current Alzheimer drug may delay the transition from Mild Cognitive Impairment (MCI) to Alzheimer's disease, but only for the first 18 months. The treatment showed modest effects on progression to Alzheimer's, but more research is needed to confirm its efficacy.
A study by Emory University researchers found that patients with mild cognitive impairment (MCI) show compromised ability to perform instrumental activities of daily living (IADLs), a trend also observed in Alzheimer's disease. Early detection and treatment can help maintain independence for individuals with MCI.
Research on statins as a treatment for Alzheimer's disease has yielded conflicting results, with some studies showing improved cognitive function and others finding no benefit. Large-scale clinical trials are needed to resolve the questions raised by these studies.
The Alzheimer's Association and NIA are expediting prevention trials for Alzheimer's by developing more efficient tools, such as home-based testing. This will reduce costs and burdens on participants while gaining valuable information about the course of cognitive changes in late life.
New research suggests that cancer-related fatigue is more closely tied to depression and impaired physical performance than previously thought. A study of 70 patients in remission found no correlation between fatigue and various physiological markers, but significant associations with depression and physical performance.
Researchers at Imperial College London have developed sugar-like molecules that mimic the body's immune defense mechanisms to prevent scarring after glaucoma eye surgery. These new drugs show a dramatic increase in success rates from 30% to 80%, offering hope for patients with this condition.
Researchers are using primate behavioral memory tasks and infrared eye-tracking technology to identify patients with mild cognitive impairment. The study aims to detect impaired memory in humans before major brain damage occurs.
A randomized study compared vitamin E and donepezil to placebo for delaying progression to Alzheimer's disease in patients with mild cognitive impairment. Patients treated with donepezil showed a modest delay in disease progression, but this effect was short-term.